Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey

Maria Gabriella Ferrandina, Rosa Pasqualina De Vincenzo, Giovanni Scambia, Giulia Amadio, Ida Paris, Caterina Ricci

Risultato della ricerca: Contributo in rivistaArticolo in rivista

2 Citazioni (Scopus)


Background Trabectedin (T) plus pegylated liposomal doxorubicin (PLD) is approved for treatment of platinum-sensitive recurrent ovarian cancer (ROC). Despite the recommendations and guidelines, variations in managing T/PLD administration in routine clinical practice cannot be excluded. We aimed at setting up an Italian survey collecting data about management of T/PLD administration in ROC patients. Methods We carried out the development of a questionnaire-based survey on routine clinical practice in the management of ROC patients administered T/PLD. The survey registered the physicians' approach to modification/discontinuation of treatment, type of modifications, reasons why, and so on. The survey was transmitted to medical oncologists and gynecologic oncologists practicing in national centers/institutions. Results Fifty-eight Italian centers/institutions returned the compiled questionnaire; participants practiced at community cancer centers or hospitals (56.9%), academic institutions (36.2%), and other settings (private clinics, etc) (6.9%). There was no statistically significant difference in the distribution of practice setting according to geographic areas. Most responders were medical oncologists (84.5%) and were members (82.8%) of at least 1 scientific society or cooperative group. Almost 31.5% of responders reported interruption of the whole treatment, mostly because of toxicity (41.2%), followed by patients' choice (29.4%), or achievement of clinical benefit (23.5%). Dose reduction was referred by 47.4% of responders. Reduction of dose for both drugs was referred by 88.5% of responders, and the extent of dose reduction ranged between 10% and 30%. Conclusions This survey highlights the gaps in transposing evidence-based or consensus guidelines in the real-world management of T/PLD administration; these findings could be useful in order to focus the attention on specific knowledge and/or experience gaps and plan pertinent educational programs.
Lingua originaleEnglish
pagine (da-a)1141-1148
Numero di pagine8
RivistaInternational Journal of Gynecological Cancer
Stato di pubblicazionePubblicato - 2017


  • Antineoplastic Combined Chemotherapy Protocols
  • Dioxoles
  • Doxorubicin
  • Female
  • Humans
  • Italy
  • Management of adverse effect
  • Neoplasm Recurrence, Local
  • Obstetrics and Gynecology
  • Oncologists
  • Oncology
  • Ovarian Neoplasms
  • Pegylated liposomal doxorubicin
  • Polyethylene Glycols
  • Practice Patterns, Physicians'
  • Recurrent ovarian cancer
  • Survey
  • Surveys and Questionnaires
  • Tetrahydroisoquinolines
  • Trabectedin


Entra nei temi di ricerca di 'Real-world management of trabectedin/pegylated liposomal doxorubicin in platinum-sensitive recurrent ovarian cancer patients: A national survey'. Insieme formano una fingerprint unica.

Cita questo